close X

ESHRE Abstracts 2019


In 2018 and 2019 our research interests included new ovarian stimulation protocols, genetic testing for infertility treatment, PGT, embryo culture, implantation success factors and many others. Three of our recent projects are being presented during ESHRE Congress 2019.

See our abstracts on:

  • Rescue in vitro maturation of oocytes shows potential to improve IVF outcome for patients under 39 years of age; Jagiełło M, Rusin M, J. Liss, K. Lukaszuk
    Download PDF
  • Time of oocyte recruitment can affect their ploidy status; Liss, J.; Knight, A. and Łukaszuk, K.
    Download PDF
  • Benefits of progesterone pituitary suppression stimulation protocol in comparison with a standard long protocol, K. Łukaszuk, A. Knight, M. Kunicki, G. Jakiel.
    Download PDF

See also some of recent scientific articles written or co-created by our team:

  • Ciebiera M, Męczekalski B, Łukaszuk K, Jakiel G. Potential synergism between ulipristal acetate and vitamin D3 in uterine fibroid pharmacotherapy - 2 case studies. Gynecol Endocrinol. 2019 Jan 11:1-5. doi: 10.1080/09513590.2018.1550062. [Epub ahead of print] PubMed PMID: 30632825.
  • Ciebiera M, Włodarczyk M, Zgliczyńska M, Łukaszuk K, Męczekalski B, Kobierzycki C, Łoziński T, Jakiel G. The Role of Tumor Necrosis Factor α in the Biology of Uterine Fibroids and the Related Symptoms. Int J Mol Sci. 2018 Dec 4;19(12). pii: E3869. doi: 10.3390/ijms19123869. Review. PubMed PMID: 30518097; PubMed Central PMCID: PMC6321234.
  • Ciebiera M, Włodarczyk M, Ciebiera M, Zaręba K, Łukaszuk K, Jakiel G. Vitamin D and Uterine Fibroids-Review of the Literature and Novel Concepts. Int J Mol Sci. 2018 Jul 14;19(7). pii: E2051. doi: 10.3390/ijms19072051. Review. PubMed PMID: 30011902; PubMed Central PMCID: PMC6073230.
  • Ciebiera M, Włodarczyk M, Wrzosek M, Wojtyła C, Błażej M, Nowicka G, Łukaszuk K, Jakiel G. TNF-α serum levels are elevated in women with clinically symptomatic uterine fibroids. Int J Immunopathol Pharmacol. 2018 Jan-Dec;32:2058738418779461. doi: 10.1177/2058738418779461. PubMed PMID: 29809057; PubMed Central PMCID: PMC5977422.
  • Kunicki M, Łukaszuk K, Liss J, Jakiel G, Skowrońska P. Demographic characteristics and AMH levels in rural and urban women participating in an IVF programme. Ann Agric Environ Med. 2018 Mar 14;25(1):120-123. doi: 10.26444/aaem/78944. Epub 2017 Oct 23. PubMed PMID: 29575864.
  • Sinderewicz E, Grycmacher K, Boruszewska D, Kowalczyk-Zięba I, Staszkiewicz-Chodor J, Łukaszuk K, Wocławek-Potocka I. Expression of genes for enzymes synthesizing lysophosphatidic acid, its receptors and follicle developmental factors derived from the cumulus-oocyte complex is dependent on the ovarian follicle type in cows. Anim Reprod Sci. 2018 May;192:242-250. doi: 10.1016/j.anireprosci.2018.03.018. Epub 2018 Mar 19. PubMed PMID: 29573844.
  • Lewandowska AE, Macur K, Czaplewska P, Liss J, Łukaszuk K, Ołdziej S. Human follicular fluid proteomic and peptidomic composition quantitative studies by SWATH-MS methodology. Applicability of high pH RP-HPLC fractionation. J Proteomics. 2019 Jan 16;191:131-142. doi: 10.1016/j.jprot.2018.03.010. Epub 2018 Mar 10. PubMed PMID: 29530678.
  • Podfigurna A, Lukaszuk K, Czyzyk A, Kunicki M, Maciejewska-Jeske M, Jakiel G, Meczekalski B. Testing ovarian reserve in pre-menopausal women: why, whom and how? Maturitas. 2018 Mar;109:112-117. doi: 10.1016/j.maturitas.2017.11.014. Epub 2017 Nov 22. Review. PubMed PMID: 29292013.
  • Liss J, Pastuszek E, Pukszta S, Hoffmann E, Kuczynski W, Lukaszuk A, Lukaszuk, K. Effect of next-generation sequencing in preimplantation genetic testing on live birth ratio. Reprod Fertil Dev. 2018 Jun 22. doi: 10.1071/RD17428
  • Plociennik L, Nelson SM, Lukaszuk A, Kunicki M, Podfigurna A, Meczekalski B, Lukaszuk K, Age-related decline in AMH is assay dependent limiting clinical interpretation of repeat AMH measures across the reproductive lifespan, Gynecological Endocrinology Vol. 34, Iss. 2, 2018
  • Iliodromiti S, Salje B, Dewailly D, Fairburn C, Fanchin R, Fleming R, Li HWR, Lukaszuk K, Hung Yu Ng E, Pigny P, Tadros T, van Helden J, Weiskirchen R, Nelson SM; Non-equivalence of anti-Müllerian hormone automated assays—clinical implications for use as a companion diagnostic for individualised gonadotrophin dosing; Hum Reprod 2017 1-6. doi: 10.1093/humrep/dex219

Learn more

close X

Our Clinical and R&D Center


INVICTA is about to build the European Family Center in prestigious polish touristic city of Sopot. The building complex will include full-service diagnostic laboratory, clinical and research and development facilities. The investment process has already started and the completion of the first building is planned for 2020.

In five ultra-modern buildings patients will have the opportunity to undergo a wide spectrum of diagnostic tests, obtain comprehensive assessment of their health status and receive specialist treatment. We aim to provide our patients with a well designed holistic diagnosis and treatment experience.

INVICTA Genetic Laboratory is our business leader with cutting-edge technologies and one of the most experienced teams. It is constantly engaged in expanding our offer of genetic testing, especially at the embryo preimplantation stage and undertakes various scientific research projects.

Our goal is to create an outstanding, unique place for patients from all over the world and provide them with holistic care. From the very beginning INVICTA has been focused on fertility diagnosis and treatment, women’s’ health, genetic diagnosis and scientific innovations in these fields. – says Dorota Białobrzeska-Łukaszuk, CEO of INVICTA. We are full of hope that The European Family Center INVICTA will be the first choice for every person searching for effective forms of diagnosis, preventive care and treatment. – she ads.

INVICTA has been operating since 2000, opening its Genetic Laboratories in 2005. Our main areas of expertise are innovative infertility diagnosis and treatment, genetic testing, scientific research and software solutions development. The investment in Sopot will be the next milestone in the company’s’ growth.

Learn more

close X

Guidelines’ experts


INVICTA’s scientific team takes part in creating treatment guidelines in infertility diagnosis and treatment –in Poland andin Europe.

Attending international conferences, leading specialistic curses and educational programs for doctors, conducting research and development projects, we’ve gathered knowledge and good practices we want to share.

Our experts co-created most important standards, among others:

Prof. Krzysztof Łukaszuk
Medical Director of INVICTA Fertility Clinics and leader of scientific board of INVICTA Group has been a leader of experts working group and a main author of Polish Society of Reproductive Medicine and Embryology Guidelines. The document describes all aspects of infertility diagnosis and treatment, including preimplantation genetic testing. Guidelines were implemented in 2018.

Joanna Liss
PhD, Director of INVICTA IVF Laboratory is actively taking part in creating ESHRE guidelines for PGT embryo biopsy; she’s a member of an international team of experts responsible for preparing and presenting ESHRE recommendations for polar body and embryo biopsy for preimplantation genetic testing (PGT).

Michał Kunicki
PhD from INVICTA Clinic in Warsaw has been invited to work on ESHRE guidelines in hormone levels based ovarian stimulation. INVICTA is a leading center to implement new stimulation protocols and run research on AMH and other hormone levels usage during stimulation process.

Learn more

close X

International conferences


1st International Conference “Increasing IVF success rates throughout every stage of the process” took place in 2018 in Gdańsk in cooperation with Invicta and Ferring Pharmaceuticals.

With this exclusive event, we had opportunity to share our knowledge and experience and meet with specialists in the IVF field from Latvia, Lithuania, Estonia, Finland and Ukraine to discuss together the subject of improving IVF success rate during IVF treatment – summarises Agnieszka Nona-Mołdawa, Business Development Director from INVICTA.

There were several lectures addressing the most important topics in current reproductive medicine. Presentations and discussions were led by our experienced specialists and scientists - Prof. Krzysztof Łukaszuk and Dr. Michał Kunicki. Experts were talking about new trends in IVF stimulation protocols and male factor during IVF treatments. An important point of the conference was the lecture of Dr Joanna Liss, head of the INVICTA IVF laboratory and Dr Sebastian Pukszta, head of molecular biology in INVICTA Genetics.

Topics presented covered issues related to the embryo quality assessment and Multidirectional Preimplantation Genetic Testing (PGT). Peter Bredbacka from Ovumia Fertinova clinic with his lecture "Biological and Technical Factors Affecting Outcome of Preimplantation Genetic Testing" was a guest lecturer during the conference. His presentation received a great deal of attention and interest.

On the second day of the conference, participants had the opportunity to visit INVICTA Clinics and INVICTA Laboratories and learn more about everyday operations. There was also an opportunity to ask questions and learn more about INVICTA standards and procedures.

Experts from INVICTA also take part in other conferences giving lectures and discussing essential issues in reproductive medicine, among others:

  • 18th World Congress of the Academy of Human Reproduction, (Dublin, Ireland, 4/2019); Lecture: Endometrium receptivity- an update on the fast growing science
  • Regional Spring Forum 2019, (Budapest, Hungary, 5/ 2019) - organized by Hungarian Society of Obstetrics and Gynecology in collaboration with Controversies in Obstetrics, Gynecology and Infertility COGI; Lecture: Poor ovarian response – what next
  • Scientific Annual Meeting of Polish Society of Reproductive Medicine and Embryology (Warsaw, Poland 9/2018); Lecture: New trends in ovarian stimulation for IVF in fertility preservation and poor responders (inc. freeze all), Implantation regulation as a chance for pregnancy.
  • XXXIII Scientific Congress of Polish Society of Ginecologists and Obstetrician (Warsaw, 9/2018); Workshop: IVF semen depend modifications.
  • 2nd Int'l Congress Bonding Embryologists to Fertility specialists to assist Nature in Overcoming Infertility, (Thessaloniki, Grecja, 8/2018); Key Note Lecture: Stimulation Protocols and the Impact on Gametes
  • The 18th World Congress Gynecological Endocrinology ISGE, (Florence, Italy, 3/2018); Lecture: Endometrial receptivity and luteal phase support
  • 1st ARC International Infertility Medical Meet, (Chennai, India, 5/2017); Lectures: Basics of hormonal assessment from the perspective of the lab & the clinician, Can we trust AMH assay?
  • 17th World Congress on Human Reproduction, (Rome, Italy, 3/2017); Lecture: Role of genetic testing in repeated pregnancy loss and repeated implantation failure; Oral abstract presentation: New possibilities of in point of care measurement by VIDAS - Anti-müllerian hormone decline from the beginning of controlled ovarian stimulation to oocyte retrieval
  • XIV Congress of Ukrainian Gynecologists (Kiew, Ukraine, 9/2017); Lecture: Clinical application of the ovarian reserve assessment considering changing diagnostic possibilities

Learn more

close X

Genetic testing


PGT all in one – one biopsy, one procedure, a lot of possibilities

Our experts developed a unique single-plot protocol with multi-directional analysis that require only a single biopsy. INVICTA Laboratory offers simultaneously tests which means minimum genetic risk with maximum performance security with only one biopsy.

With PGT we can at the same time diagnose:

  • Aneuploidy
  • Single gene diseases
  • Reciprocal Translocations
  • Robertsonian Translocations
  • X-lined Disorders
  • Sex determination (in the case of medical recommendations)

Benefits of PGT + PGT-A

  • single embryo biopsy - eliminating unnecessary risks
  • maximum information from the minimum sample
  • comprehensive report

Open Frame™

Personalized Carrier Screening Test. A Universal tool that allows planning comprehensive genetic diagnostics personalized for each Patient. The Open Frame™ approach allows identification of over 163,000 of all known and described mutations, examination of 15,189 known genes and 331,130 of all exons in the human genome.

all known and described mutations
all exons in the human genome
all known gemes

This solution is dedicated to specialists who expect flexible approach, efficient cooperation and “tailor made” solutions in their daily work. It is based on the state-of-the-art Next Generation Sequencing (NGS) technique which is currently considered the reference method for all other DNA analysis techniques.

FertiGenes Test™

It has been designed for couples seeking to become parents. The test allows for determination of mutations present in the woman’s and man’s DNA and how they could affect the pregnancy and the baby’s health.

FertiGenesTest™. Female Fertility
Prothrombin (20210G>A)
CFTR (dele2,3, delF508)
MTHFR (C677T, A1298C)

FertiGenesTest™. Male Fertility
AZF according to EMQN best practice guidelines
CFTR (dele2,3, delF508)

Learn more

close X

Contact us

Agnieszka Nona-Mołdawa
Master of Molecular Biology
Space Technologies Explorer :)

This email address is being protected from spambots. You need JavaScript enabled to view it.

phone +48 696 059 658